Vioxx Whistleblower Voices Concern over Ketek Antibiotic




The FDA employee known for voicing concerns about his agency's handling of Vioxx has raised similar red flags about the approval and continued marketing of the antibiotic Ketek.

In a letter to the editor published in the Nov. 23 issue of The New England Journal of Medicine, Dr. David Graham suggests that patients and healthcare providers reconsider the use of Ketek to treat respiratory infections because of data indicating that the drug poses a high risk of liver-related injuries.

Graham's letter was issued in response to a study touting the efficacy of Ketek in patients with acute asthma exacerbations, a …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference: Managing Mass Torts, Status of Key Litigations and Lessons Learned

March 29, 2023 - Tucson, AZ
Hotel Details in Tucson, Arizona, to be Announced

MORE DETAILS



HarrisMartin's New Jersey Asbestos Litigation Conference

March 03, 2023 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS